Drug made in Kalamazoo could be first to treat Parkinson’s | Woodtv.com

GRAND RAPIDS, Mich. (WOOD) — A diabetes drug developed in Kalamazoo is showing promise in treating Parkinson’s disease. The Van Andel Research Institute says human trials will begin next year for MSDC-0160, which was created […]

Read On ›

Van Andel Institute: Diabetes drug slows experimental Parkinson’s disease progression, human trials to begin next year

GRAND RAPIDS, Mich. (Dec. 7, 2016)—A new investigational drug originally developed for type 2 diabetes is being readied for human clinical trials in search of the world’s first treatment to impede the progression of Parkinson’s […]

Read On ›

Metabolic Solutions Development Company Highlights Plans for MSDC-0602 in NASH and Polycystic Kidney Disease

 KALAMAZOO, Mich., March 18, 2015 – Metabolic Solutions Development Company (MSDC), an emerging biopharmaceutical company developing first in class therapeutics to treat diseases associated with metabolic dysfunction, today announced that Stephen Benoit, CEO, will present […]

Read On ›

Metabolic Solutions Development Company Appoints Robert L. Zerbe, MD to Board of Managers

KALAMAZOO, Mich., October 23, 2014 – Metabolic Solutions Development Company, LLC (MSDC) announced today that it has appointed Robert L. Zerbe, MD to its Board of Managers. Dr. Zerbe co-founded and is chief executive officer […]

Read On ›

MSDC Presents Phase 2a Clinical Trial Results at the 14th International Conference on Alzheimer’s Drug Discovery

 KALAMAZOO, Mich., /Sept. 9, 2013 – Metabolic Solutions Development Company, LLC (MSDC) has announced that Jerry Colca, PhD, co-founder and chief scientific officer of MSDC, will present results of a Phase 2a study on September […]

Read On ›

Metabolic Solutions Development Company Awarded Funding by The Michael J. Fox Foundation

KALAMAZOO, Mich., Feb. 7, 2013 – Metabolic Solutions Development Company, LLC (MSDC) announced today that it has received an award from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to conduct preclinical research on […]

Read On ›

Metabolic Solutions Development Company Announces Publication of Phase 2b Data in Clinical Pharmacology & Therapeutics

KALAMAZOO, Mich., Jan. 24, 2013 – Metabolic Solutions Development Company, LLC (MSDC) announced today the publication of data from a Phase 2b study of the company’s prototype insulin sensitizer in patients diagnosed with type 2 […]

Read On ›

MSDC Presents Update on Ongoing Clinical Evaluation of First in Class mTOT Modulator™ in Mild Alzheimer’s Disease at 13th International Conference on Alzheimer’s Drug Discovery

KALAMAZOO, Mich., Sept. 7, 2012 /PRNewswire/ — Metabolic Solutions Development Company, LLC (MSDC) will provide an update on the clinical evaluation of MSDC-0160, a first in class mTOT Modulator™ that is being investigated in an […]

Read On ›

Researchers Study Potential New Therapeutic Target for Alzheimer’s Disease

KALAMAZOO, Mich., June 21, 2012 – Physicians at medical centers in Kalamazoo and Grand Rapids are helping to identify interested individuals for participation in a clinical trial of a novel drug therapy for patients with […]

Read On ›

Metabolic Solutions Development Company Novel Insulin Sensitizer Meets Phase 2b Study Endpoints And Affirms New Mechanism Of Action

PHILADELPHIA, June 9, 2012 – Metabolic Solutions Development Company, LLC (MSDC) presented Phase 2b results for MSDC-0160 today at the 72nd Scientific Sessions of the American Diabetes Association. The data showed this novel once-a-day oral […]

Read On ›

Metabolic Solutions Development Company Receives $1.1 Million NIH Grant to Further Investigate MSDC-0602 for the Treatment of Fatty Liver Disease

Kalamazoo, Mich. (October 6, 2011) – Metabolic Solutions Development Company, LLC (MSDC) announced today it has received a $1.1 million multi-year Small Business Technology Transfer Program (STTR) grant from the National Institute on Alcohol Abuse […]

Read On ›

Metabolic Solutions Development Company Reports Positive Top-Line Results from Phase 2A Study of its Second Compound to Treat Type 2 Diabetes

Kalamazoo, Mich. (September 08, 2011) – Metabolic Solutions Development Company, LLC (MSDC) confirmed today the potential of MSDC-0602 to achieve significant glucose control in type 2 diabetes patients and increase insulin sensitivity based on preliminary […]

Read On ›

A tale of proteins and cells: Metabolic Solutions is trying to write next chapter with new diabetes, heart treatments – Kalamazoo Gazette

Kalamazoo, Mich. (July 24, 2011) – Metabolic Solutions Development Company was recently featured in the Kalamazoo Gazette putting the spotlight on the company’s efforts to develop novel treatments for metabolic diseases. Read the complete Kalamazoo […]

Read On ›

MSDC Receives $773,000 from the Alzheimer’s Drug Discovery Foundation to Fund Phase 2a Trial

Kalamazoo, Mich. (July 06, 2011) – Metabolic Solutions Development Company (MSDC), a drug discovery and development company exploiting novel molecular targets to treat metabolic diseases, announced today that it has received a $773,000 grant from […]

Read On ›

MSDC to Present Recent Findings on the Therapeutic Potential of Increasing Brown Fat in the Treatment of Diabetes at Annual American Diabetes Association Conference

Kalamazoo, Mich. (June 21, 2011) – Metabolic Solutions Development Company (MSDC) and collaborators will present their research providing insights into the therapeutic potential of increasing brown adipose tissue in the treatment of diabetes and the […]

Read On ›

MSDC Launches Phase 2A Trial of Its Second Compound to Treat Type 2 Diabetes

Kalamazoo, Mich. (March 29, 2011) – Metabolic Solutions Development Company (MSDC), a drug discovery and development company exploiting novel molecular targets to treat metabolic diseases, announced today that it has launched a Phase 2a trial […]

Read On ›